Welcome to our dedicated page for In8Bio SEC filings (Ticker: INAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IN8bio, Inc. (Nasdaq: INAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta (γδ) T cell therapies and engagers for cancer and autoimmune diseases, and its filings offer structured insight into this development activity and its status as a Nasdaq-listed issuer.
IN8bio uses Form 8-K current reports to announce material events such as clinical data updates, preclinical presentations and financial results. For example, the company has filed 8-Ks referencing presentations of INB-200 and INB-400 glioblastoma data at the Society for Neuro-Oncology (SNO) Annual Meeting, new preclinical data from its INB-619 γδ T cell engager program at the American College of Rheumatology (ACR) Convergence Meeting, and quarterly financial results press releases. Another 8-K documents Nasdaq’s confirmation that IN8bio regained compliance with the minimum bid price listing rule, and reiterates that its common stock trades on The Nasdaq Stock Market LLC under the symbol INAB.
Through IN8bio’s periodic reports and exhibits referenced in 8-Ks, investors can review information on research and development spending, general and administrative expenses, net loss, cash position and stockholders’ equity, as well as narrative descriptions of pipeline programs such as INB-100, INB-200, INB-400, INB-619 and the INB-600 platform. These filings also include risk factor discussions and forward-looking statements that frame the uncertainties inherent in clinical-stage biopharmaceutical development.
On Stock Titan, INAB filings are updated in line with new submissions to EDGAR. AI-powered tools can help summarize lengthy documents, highlight key clinical and financial disclosures, and surface specific items such as clinical trial updates embedded in exhibits to Form 8-K. Users interested in IN8bio’s regulatory and financial history can review this archive to track how the company describes its γδ T cell programs, manufacturing capabilities, Nasdaq listing status and other material developments over time.
This Amendment No. 2 to a Schedule 13G discloses that Transcend Partners Opportunity Fund I LLC beneficially owns 107,416 shares of IN8bio common stock, representing 2.6% of the class. The percentage is calculated using 4,078,139 shares outstanding as reported as of June 30, 2025. The Reporting Person reports no sole voting or sole dispositive power and instead reports shared voting and shared dispositive power over the shares. Actions regarding these shares require a majority vote of Transcend's managing members, each of whom disclaims beneficial ownership. The amendment is a disclosure of beneficial ownership rather than an indication of control.
IN8bio, Inc. Schedule 13G/A discloses that William Tai-Wei Ho beneficially owns 151,223 shares of common stock, representing 3.7% of the class on a diluted basis. The position comprises 85,112 shares held of record, 4,866 shares held by his minor children, 3,648 shares held by other relatives over which he holds an irrevocable proxy, plus 47,914 options and 9,683 warrants that are immediately or imminently exercisable.
The filing also details voting and dispositive power: 142,709 shares with sole voting and dispositive power and smaller amounts reported as shared power. This amendment updates ownership disclosure but does not show a >5% stake or an intent to control the company.